Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diphtheria Toxin | 11 | 2009 | 30 | 1.520 |
Why?
|
| Sepsis | 8 | 2016 | 163 | 1.330 |
Why?
|
| Sirtuin 1 | 5 | 2014 | 36 | 1.310 |
Why?
|
| Recombinant Fusion Proteins | 11 | 2005 | 122 | 1.280 |
Why?
|
| Energy Metabolism | 5 | 2019 | 150 | 0.900 |
Why?
|
| Glioblastoma | 6 | 2009 | 158 | 0.880 |
Why?
|
| Epidermal Growth Factor | 5 | 2005 | 25 | 0.850 |
Why?
|
| Brain Neoplasms | 5 | 2009 | 636 | 0.730 |
Why?
|
| Interleukin-13 | 3 | 2009 | 29 | 0.680 |
Why?
|
| Inflammation | 7 | 2019 | 500 | 0.660 |
Why?
|
| Monocytes | 3 | 2019 | 118 | 0.650 |
Why?
|
| Epigenesis, Genetic | 4 | 2014 | 107 | 0.570 |
Why?
|
| Transcription Factor RelB | 4 | 2014 | 26 | 0.550 |
Why?
|
| Sirtuins | 2 | 2016 | 21 | 0.480 |
Why?
|
| Endotoxins | 4 | 2014 | 36 | 0.450 |
Why?
|
| Sirtuin 3 | 1 | 2014 | 3 | 0.430 |
Why?
|
| Cell Nucleus | 1 | 2014 | 111 | 0.410 |
Why?
|
| Drug Resistance | 2 | 2011 | 42 | 0.400 |
Why?
|
| Exotoxins | 2 | 2003 | 12 | 0.400 |
Why?
|
| Signal Transduction | 3 | 2016 | 716 | 0.380 |
Why?
|
| Mitochondria | 1 | 2014 | 207 | 0.370 |
Why?
|
| Interleukin-3 | 4 | 2004 | 13 | 0.370 |
Why?
|
| Antineoplastic Agents | 4 | 2004 | 595 | 0.360 |
Why?
|
| Fatty Acids | 1 | 2012 | 100 | 0.350 |
Why?
|
| Glucose | 1 | 2012 | 158 | 0.340 |
Why?
|
| Promoter Regions, Genetic | 2 | 2011 | 203 | 0.330 |
Why?
|
| Cytotoxins | 1 | 2009 | 13 | 0.290 |
Why?
|
| Cell Hypoxia | 1 | 2009 | 43 | 0.280 |
Why?
|
| Cell Line | 4 | 2014 | 443 | 0.280 |
Why?
|
| Oxygen | 1 | 2009 | 134 | 0.270 |
Why?
|
| Toll-Like Receptor 4 | 3 | 2012 | 46 | 0.250 |
Why?
|
| Lipopolysaccharides | 4 | 2019 | 113 | 0.250 |
Why?
|
| Animals | 15 | 2016 | 8165 | 0.240 |
Why?
|
| Receptors, Interleukin-3 | 3 | 2004 | 6 | 0.230 |
Why?
|
| Glioma | 2 | 2005 | 137 | 0.230 |
Why?
|
| Mice | 7 | 2014 | 2544 | 0.230 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2011 | 213 | 0.220 |
Why?
|
| Humans | 23 | 2019 | 32284 | 0.220 |
Why?
|
| Cell Line, Tumor | 6 | 2009 | 726 | 0.220 |
Why?
|
| NAD | 3 | 2016 | 28 | 0.200 |
Why?
|
| Gene Expression Regulation | 4 | 2016 | 478 | 0.200 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2003 | 4 | 0.200 |
Why?
|
| Glycolysis | 2 | 2014 | 17 | 0.200 |
Why?
|
| Leukocytes | 3 | 2014 | 59 | 0.190 |
Why?
|
| Mice, Inbred C57BL | 3 | 2014 | 776 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 4 | 2004 | 165 | 0.160 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2005 | 26 | 0.150 |
Why?
|
| Receptors, Interleukin | 3 | 2003 | 16 | 0.150 |
Why?
|
| MicroRNAs | 2 | 2011 | 181 | 0.140 |
Why?
|
| Oxidative Phosphorylation | 2 | 2015 | 30 | 0.140 |
Why?
|
| Spleen | 2 | 2014 | 82 | 0.130 |
Why?
|
| Brain | 1 | 2003 | 966 | 0.120 |
Why?
|
| Histones | 3 | 2011 | 50 | 0.120 |
Why?
|
| Transcription, Genetic | 3 | 2011 | 141 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2004 | 56 | 0.110 |
Why?
|
| Protein Biosynthesis | 2 | 2015 | 42 | 0.110 |
Why?
|
| RNA-Binding Proteins | 2 | 2012 | 67 | 0.110 |
Why?
|
| Immunity | 1 | 2014 | 19 | 0.100 |
Why?
|
| Oxygen Consumption | 1 | 2014 | 140 | 0.100 |
Why?
|
| Gene Silencing | 2 | 2011 | 45 | 0.100 |
Why?
|
| Transcription Factor RelA | 2 | 2011 | 22 | 0.100 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 1073 | 0.100 |
Why?
|
| Receptors, Interleukin-13 | 2 | 2003 | 9 | 0.100 |
Why?
|
| Interleukin-13 Receptor alpha1 Subunit | 2 | 2003 | 11 | 0.100 |
Why?
|
| Mice, Knockout | 1 | 2014 | 441 | 0.100 |
Why?
|
| Heterochromatin | 2 | 2011 | 12 | 0.100 |
Why?
|
| Flow Cytometry | 2 | 2003 | 184 | 0.100 |
Why?
|
| Phenotype | 1 | 2014 | 619 | 0.090 |
Why?
|
| Monocyte-Macrophage Precursor Cells | 1 | 2012 | 3 | 0.090 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2012 | 7 | 0.090 |
Why?
|
| Alzheimer Disease | 1 | 2016 | 281 | 0.090 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2012 | 12 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 24 | 0.090 |
Why?
|
| Heat-Shock Proteins | 1 | 2012 | 37 | 0.090 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 54 | 0.090 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 255 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2012 | 148 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2012 | 184 | 0.080 |
Why?
|
| Protein Stability | 1 | 2011 | 26 | 0.080 |
Why?
|
| Cytokines | 1 | 2012 | 236 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2011 | 41 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 3 | 2005 | 62 | 0.080 |
Why?
|
| Macrophages | 1 | 2011 | 164 | 0.080 |
Why?
|
| Nucleosomes | 1 | 2009 | 4 | 0.080 |
Why?
|
| Furin | 1 | 2009 | 3 | 0.070 |
Why?
|
| Immunotoxins | 1 | 2009 | 18 | 0.070 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2009 | 12 | 0.070 |
Why?
|
| Aging | 1 | 2015 | 941 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 1159 | 0.070 |
Why?
|
| Leukemia, Myeloid | 2 | 2004 | 26 | 0.060 |
Why?
|
| Metabolome | 2 | 2019 | 37 | 0.060 |
Why?
|
| Acute Disease | 2 | 2004 | 253 | 0.060 |
Why?
|
| Blood Urea Nitrogen | 1 | 2005 | 12 | 0.050 |
Why?
|
| Nitrogen | 1 | 2005 | 10 | 0.050 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 73 | 0.050 |
Why?
|
| Necrosis | 1 | 2005 | 52 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 113 | 0.050 |
Why?
|
| Homeostasis | 2 | 2016 | 130 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2005 | 199 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2005 | 285 | 0.050 |
Why?
|
| Sequence Deletion | 1 | 2004 | 38 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 40 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 64 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2004 | 88 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2004 | 70 | 0.050 |
Why?
|
| Pseudomonas | 1 | 2003 | 6 | 0.050 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2003 | 6 | 0.050 |
Why?
|
| Receptors, Transferrin | 1 | 2003 | 10 | 0.050 |
Why?
|
| Microscopy, Confocal | 1 | 2003 | 73 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2003 | 66 | 0.050 |
Why?
|
| Protein Binding | 1 | 2004 | 243 | 0.050 |
Why?
|
| Astrocytoma | 1 | 2003 | 28 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 93 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2003 | 106 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 293 | 0.050 |
Why?
|
| Kinetics | 1 | 2003 | 248 | 0.050 |
Why?
|
| Immune Tolerance | 2 | 2014 | 66 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2003 | 131 | 0.040 |
Why?
|
| Liver | 1 | 2005 | 491 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2003 | 156 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 298 | 0.040 |
Why?
|
| Kidney | 1 | 2005 | 520 | 0.040 |
Why?
|
| Bone Marrow Cells | 2 | 2014 | 112 | 0.040 |
Why?
|
| Time Factors | 1 | 2005 | 2196 | 0.040 |
Why?
|
| Nucleotides | 1 | 2019 | 17 | 0.040 |
Why?
|
| Carnitine | 1 | 2019 | 14 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2019 | 21 | 0.040 |
Why?
|
| Female | 5 | 2015 | 19954 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2019 | 67 | 0.040 |
Why?
|
| Amino Acids | 1 | 2019 | 52 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 104 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2005 | 3410 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2016 | 69 | 0.030 |
Why?
|
| Ribosomes | 1 | 2015 | 11 | 0.030 |
Why?
|
| CpG Islands | 1 | 2015 | 44 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 152 | 0.030 |
Why?
|
| Autophagy | 1 | 2015 | 55 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2014 | 17 | 0.030 |
Why?
|
| Carbazoles | 1 | 2014 | 6 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2014 | 27 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2016 | 241 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 138 | 0.030 |
Why?
|
| Intestine, Small | 1 | 2014 | 44 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2015 | 144 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2014 | 75 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2014 | 81 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2014 | 112 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2014 | 190 | 0.020 |
Why?
|
| Macaca fascicularis | 2 | 2004 | 542 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 33 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2011 | 20 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 151 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 246 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 297 | 0.020 |
Why?
|
| Response Elements | 1 | 2009 | 16 | 0.020 |
Why?
|
| Histocompatibility Antigens | 1 | 2009 | 11 | 0.020 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2009 | 27 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2011 | 499 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 3896 | 0.020 |
Why?
|
| Models, Biological | 1 | 2009 | 403 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 98 | 0.010 |
Why?
|
| Half-Life | 1 | 2004 | 24 | 0.010 |
Why?
|
| Anorexia | 1 | 2004 | 6 | 0.010 |
Why?
|
| Vasculitis | 1 | 2004 | 26 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 97 | 0.010 |
Why?
|
| Adenosine Diphosphate Ribose | 1 | 2004 | 2 | 0.010 |
Why?
|
| Drug Stability | 1 | 2004 | 11 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 2004 | 33 | 0.010 |
Why?
|
| Plasmids | 1 | 2004 | 53 | 0.010 |
Why?
|
| Haplorhini | 1 | 2004 | 75 | 0.010 |
Why?
|
| Genes, erbB-1 | 1 | 2003 | 14 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 256 | 0.010 |
Why?
|
| Injections | 1 | 2003 | 72 | 0.010 |
Why?
|
| Male | 2 | 2015 | 19434 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 293 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 368 | 0.010 |
Why?
|
| Pancreas | 1 | 2003 | 107 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 286 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2004 | 211 | 0.010 |
Why?
|
| Gene Expression | 1 | 2004 | 345 | 0.010 |
Why?
|
| Aged | 1 | 2015 | 10257 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2003 | 105 | 0.010 |
Why?
|
| Middle Aged | 1 | 2015 | 11843 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 709 | 0.010 |
Why?
|